Our objective was to define responder criteria using an anchor-based approach for frequency of cataplexy attacks and excessive daytime sleepiness in patients with narcolepsy undergoing sodium oxybate treatment. We used pooled data from two randomized, placebo-controlled, double-blind, multicentre 4-and 8-week trials of sodium oxybate for narcolepsy with cataplexy and analysed using receiver operator characteristics analysis. The percentage change in frequency of weekly cataplexy attacks and the Epworth Sleepiness Scale outcomes were compared with Clinical Global Impression of Change ratings, used as the anchor to define true response. Participants (n = 336) were 39% male, 89% white, with a mean age of 41.5 (15.3) years, reporting a median of 20.5 cataplexy attacks per week and a mean Epworth Sleepiness score of 17.5 at baseline. A majority (51%) were Much Improved or Very Much Improved based on Clinical Global Impression of Change ratings, considered a true response to treatment. Area under the curve values for % reduction in cataplexy attacks (77%) and % change in sleepiness score (78%) supported response definition thresholds of 46% and 12%, respectively. Classification using either response definition agreed with the anchor for approximately 71% of participants. Cataplexy response definition was more sensitive (cataplexy = 0.77, Epworth Sleepiness Scale = 0.69), while sleepiness was more specific (cataplexy = 0.66, Epworth Sleepiness Scale = 0.75). Both responder definitions showed a dose-response relationship with sodium oxybate, demonstrating their validity using an external criterion. Weekly cataplexy attacks and Epworth Sleepiness Scale can be used to help document clinical response to narcolepsy treatment using criteria of 46% and 12% reductions, respectively.
IN TROD UCTI ON
Patients with narcolepsy experience debilitating symptoms, including excessive daytime sleepiness and cataplexy attacks. The former is commonly measured via self-report using the Epworth Sleepiness Scale (ESS), and the latter may be tracked daily by use of a cataplexy diary. Patients' report of symptoms and their improvement are increasingly recognized as important for clinical trials that establish the efficacy of new drugs. However, it is not always clear what constitutes a clinically relevant response to treatment in research or clinical settings. There has been evolving discourse on the best method for defining meaningful change. While clinical trials are often analysed by comparing group means from a treatment versus control group, the difference in change between groups is not necessarily the relevant level of change for an individual.
In 2009, the Food and Drug Administration (FDA) published a guidance to industry for using patient-reported outcomes (PROs) in clinical trials that test drugs and medical devices for efficacy (US Department of Health and Human Services, 2009) , and others have also contributed to this discussion (Cappelleri and Bushmakin, 2014; McLeod et al., 2011; Snapinn and Jiang, 2007; Wyrwich et al., 2013) . The FDA emphasized a need for each PRO to have a corresponding responder definition (RD) , that is, an empirically determined threshold that identifies individual-level meaningful change over a specified time period. Such RDs should be established a priori using anchor-based, empirical methods for use in clinical trials to describe the proportions of individuals within the treatment conditions showing a meaningful response. RD criteria may also be useful to clinicians to document treatment efficacy, inform dose titration, and help counsel patients regarding symptom management and safety concerns. To our knowledge, there have been no published RDs for narcolepsy PROs.
Our goal in this analysis was to use empirical anchorbased methods to establish RDs for excessive daytime sleepiness and frequency of cataplexy attacks using pooled data from two Phase III randomized double-blind controlled trials of sodium oxybate for the treatment of narcolepsy. We assessed if either PRO was more reliably associated with an anchor measure of clinical improvement, the Clinical Global Impression of Change (CGI-c), and if the RDs based on these PROs show agreement with each other. Finally, we validated the PRO RDs by showing that the proportions of responders based on the PRO RDs differ by dose of sodium oxybate.
MATERI ALS AND METHODS
This secondary analysis used data from two double-blinded randomized controlled trials testing sodium oxybate at a range of doses versus placebo to assess potential RD thresholds for symptoms of excessive daytime sleepiness and frequency of cataplexy attacks. These multicentre trials were conducted at 42 sites from 1997 to 1998 and 2000 to 2004, and have been described in detail elsewhere. Briefly, participants in the two trials were 16 years old or older, had a positive history of narcolepsy with current symptoms of excessive daytime sleepiness, cataplexy, and recurrent sleep attacks. Reflecting real world clinical practice, those taking stable doses of stimulants, approximately 80%, were permitted to continue the medication during their trials. Hypnotic and anti-cataplectic medications were gradually discontinued with an additional washout period. In the 1997-1998 4-week trial (n = 136), the total nightly doses investigated were 3, 6 and 9 g. In the 2000-2004 8-week trial (n = 228), the total nightly doses were 4.5, 6 and 9 g, with the first 4 weeks incorporating a titration procedure for the two higher dose groups. Participants who completed the measures of excessive daytime sleepiness or frequency of cataplexy attacks at baseline and endpoint who were also assessed by physicians at endpoint are included in these analyses (n = 322-327; 88.5-89.8% of the enrolled participants depending on the outcome).
Measures
The Clinical Global Impression of Severity (CGI-s) and CGI-c measures were rated by the blinded clinician at baseline and at the study endpoint, respectively. The response options for the CGI-s ranged from normal to extremely ill. The CGI-c rating, made at the study endpoint, referenced the baseline CGI-s rating, and used response options of Very Much Worse, Much Worse, Minimally Worse, No Change, Minimally Improved, Much Improved, Very Much Improved.
The CGI-c ratings of Much Improved and Very Much Improved were considered a favourable response to treatment, while the ratings of Minimally Improved, No Change, Very Much Worse, Much Worse, or Minimally Worse were considered a non-favourable response. The dichotomized version of the CGI-c served as the anchor measure of treatment response for assessing the RD thresholds for excessive daytime sleepiness and reduction in the frequency of cataplexy attacks.
The ESS (Johns, 1991) was used to measure excessive daytime sleepiness. Conceptually, this self-administered scale measures sleep propensity by asking individuals to rate their likelihood of falling asleep in eight soporific situations, shows acceptable internal consistency, and has been used in clinical trials with patients with narcolepsy detecting a range of response to treatment effect sizes (Weaver, 2001) . Previous research has suggested a score of 11 or more has a sensitivity of 93.5% and specificity of 100% for distinguishing excessive daytime sleepiness from normal daytime sleepiness (Johns, 2000) . Coefficient alpha was 0.76 for the baseline administration using the current data.
Daily patient diaries included detailed descriptions of the symptoms to be recorded, including frequency of cataplexy events, nocturnal awakenings, total sleep time, hypnagogic hallucinations and sleep paralysis, as well as any adverse events. Participants were trained to record symptoms if they occurred, and were instructed to make diary entries every morning and evening. Cataplexy attacks were defined as having sudden onset, precipitated by emotion, localizable to a specific part of the body, and did not occur during a sleep attack (i.e. patient remained lucid and aware; Xyrem â International Study Group, 2005) . Baseline and endpoint frequencies of cataplexy attacks were based on 2 weeks of diary entries and calculated as number of cataplexy attacks per week. The intraclass correlation of daily attacks was 0.739.
Statistical analyses
A preliminary step was to consider the formula for calculating our outcomes, for example, simple change scores or % improvement from baseline. The distributions of baseline and follow-up measures of our two outcomes, ESS and cataplexy frequency, as well as their change scores, were examined. ESS scores were limited in range by the nature of the measure with a possible range of 0-24 and the distributions were approximately normal. However, the frequency of cataplexy had great variability with a range of 0-912 cataplexy events per week; an extreme range in the difference between baseline and endpoint was also evident (À310 to 97). Due to this variability, we chose to compute change scores as the % change from the baseline measure for both the outcomes. A second preliminary task was to assess if the correlations between the anchor measures and outcomes were substantial and similar across the two studies ª 2017 European Sleep Research Society contributing to the pooled dataset. We examined if the Spearman correlations between the ordinal version of CGI-c, our anchor measure, and each outcome were significantly different between the 4-and 8-week trials using Fisher's ztransformation (Snedecor and Cochran, 1989) . We described the sample and compared responders and non-responders, as defined by the dichotomized anchor, CGI-c, using t-tests and chi-squared statistics.
Our primary approach for identifying RD thresholds was an anchor-based receiver operator characteristic (ROC) analysis. The dichotomized anchor measure of response, the CGIc, was regressed onto the percent change scores for each measure in separate logistic models with the ROC graph plotting sensitivity, the percentage classified as improved out of the total improved, versus 1 À specificity, the false positive rate, for each value in the range observed. We compared the Liu, Youden and (0,1) optimization criteria for choosing cut-off points that maximized the joint sensitivity and specificity for identifying responders based on the product of sensitivity and specificity, their sum, and the nearest distance to perfect sensitivity and specificity, respectively (Clayton, 2013; Fluss et al., 2005; Liu, 2012; Youden, 1950) . We compared the ESS and cataplexy frequency percent change from baseline to assess if either outcome was more or less associated with CGI-c. The area under the curve (AUC) statistics were calculated for the ESS and cataplexy frequency percent change scores, along with 95% confidence intervals, and were tested for a statistically significant difference using a non-parametric approach for measures assessed on the same sample (DeLong et al., 1988) . In the Results, we present agreement and kappa statistics based on our selected cut-offs, as well as sensitivity and specificity.
Distribution methods were used as a secondary approach to identifying responder thresholds. We used the baseline standard deviations (SDs) and calculated 0.5 SD as well as a standard error of measurement, SEM ¼ SD ffiffiffiffiffiffiffiffiffiffiffi 1 À a p where alpha represents a reliability estimate (McLeod et al., 2011) . The SD for cataplexy frequency is calculated excluding the extreme upper and lower 2.5%, due to the extreme outliers.
Finally, we include PRO RD results by treatment dose as validation of our approach. In preparation, we compared the outcomes for groups receiving low total nightly doses, 3 g (used only in the 4-week trial) and 4.5 g (used only in the 8-week trial) using t-tests [ESS % change: t(87) = 0.91, P = 0.3677; cataplexy % change: t(89) = À0.19, P = 0.8519], and thus combined these lowest dose groups. Other doses were consistent across the 4-and 8-week trials. Cumulative distribution plots of each outcome by the resulting four dose groups are shown to display all possible RD thresholds as well as our selected RD thresholds indicated with a vertical line. We tested the RD outcomes by treatment groups using logistic regression testing for dose trend as well as the four levels of dose using placebo as the reference group. All analyses were performed with Stata, version 12.1 (StataCorp, 2011) .
Ethics
The studies contributing data to these analyses were conducted in eight countries in accordance with the Helsinki Declaration of 1975, revised in 1997 Each participating trial centres' institutional review board approved the studies, and participants gave written informed consent (The U.S. Xyrem â Multicenter Study Group, 2002; Xyrem International Study Group, 2005) .
RESULTS
We began by computing the Spearman correlations of our anchor measure of response, the CGI-c, with our PROs, percent change measures of ESS and frequency of cataplexy attacks, and found moderate associations that were not significantly different across the 4-and 8-week trials (ESS: 4-week rho = 0.57, 8-week rho = 0.52, Fisher's z = 0.61, P = 0.5419 test comparing difference between correlations; cataplexy: 4-week rho = 0.61, 8-week rho = 0.50, Fisher's z = 1.39, P = 0.1645). These moderate correlations support the CGI-c as an appropriate anchor. Data were pooled because the relationships of the anchor (CGI-c) with the ESS and cataplexy outcomes were similar over the two trials (Spearman rho = 0.53, P < 0.001 and 0.55, P < 0.001 for CGI-c with ESS and cataplexy, respectively, for pooled data). A multiple linear model regressing CGI-c on both ESS and cataplexy, with extreme negative cataplexy values truncated to the 5th percentile, showed an adjusted R 2 = 0.34 with both ESS and cataplexy significantly related to CGI-c [P < 0.001, 95% confidence intervals for b coefficients ESS (0.01, 0.02), cataplexy (0.006, 0.01), standardized beta = 0.34 for both]. A description of the aggregated sample is presented in Table 1 . The sample was 39% male and 89% white; responders and non-responders had similar distributions. However, responders were slightly younger than non-responders [mean (SD) age responders = 39.7 (14.9) years; non-responders = 43.3 (15.6) years, P = 0.03]. Overall, severity did not differ between responders and non-responders, with a vast majority of participants assessed as moderately to markedly ill. Similarly, the baseline measures of the PROs did not differ based on responder status. The mean (SD) ESS score at baseline is 17.5 (3.8) points, which is indicative of severe daytime sleepiness. The median frequency of cataplexy attacks per week was 20.5, with 50% of the sample having between 11.5 and 38 episodes per week. At follow-up, the groups classified by CGI-c were significantly different on percent change measures of ESS and frequency of cataplexy attacks; findings that are consistent with the moderate correlations reported above and the AUC results reported below.
Response definition threshold
The results of the ROC models are shown in Fig. 1 and Table 2 . Fig. 1 displays ROC curves for both ESS and ª 2017 European Sleep Research Society cataplexy percent change scores. These outcomes were similarly related to the dichotomous anchor measure indicating treatment response, the CGI-c, with no significant difference noted between the AUCs, v 2 (1) = 0.10, P = 0.75.
The AUCs are indicative of the reliability of the association of each PRO with the anchor measure, and indicate a strong relationship with the anchor response definition. The empirical cut-off points estimated using all three optimization criteria (i.e. Liu, Youden, nearest to 0,1) yielded the same estimates, shown in Table 2 . We examined the empirical cutoff points separately by trial, and found lower thresholds for improvement in the 4-week trial compared with the 8-week trial. The ESS cut-off point for the 4-week trial was similar to the pooled data, whereas the cataplexy cut-off point for the 8-week trial was closer to the pooled data. We chose our RD thresholds by rounding to the next largest whole number based upon the pooled data. Based on these thresholds, we created dichotomized indicators of response for ESS (ESS_RD) and cataplexy (cataplexy_RD). Note that cataplexy_RD is slightly more sensitive, while the ESS_RD is more specific. Agreement and kappa statistics were comparable for the measures compared with the CGI-c anchor, and slightly lower when compared with each other (agreement = 69.28%, kappa = 0.39). The distribution-based thresholds are based on the original scale of the ESS and cataplexy frequency measures. For ESS, the 0.5 SD is 1.9 and the SEM is the same. Cataplexy frequency SD = 24.6 was based on a truncated range of 5.25-123 (95% of sample) due to extreme values. The distribution-based thresholds for cataplexy frequency are 0.5 SD = 12.3 and SEM = 12.6. As a point of comparison, the ESS_RD at the sample mean would indicate a 2.1 point decrease in the ESS score. Similarly, the cataplexy_RD at the median would be equivalent to a decrease of 9.4 cataplexy attacks per week and a decrease of 17.9 attacks for those at the 75th percentile.
Validation
While our anchor measure of clinical improvement and RD thresholds were derived without regard for treatment condition or dose, we present these findings here as a validation of our approach. Both PROs showed dose-response relationships in the pooled data. Fig. 2 displays the cumulative distribution functions of placebo and other dose levels used in these studies for all possible thresholds. The points at which each curve is dissected by the red line can be used to assess how the proportion of responders differs by treatment dose. For example, the placebo group shows that approximately 30% were responders based on ESS_RD, whereas almost 80% of patients in the highest dose group were responders (Fig. 2a) 
DISCUSSION
In this secondary analysis of clinical trial data, we have empirically established RDs that correspond to a CGI-c assessment of Much Improved or Very Much Improved with fair and consistent accuracy for two debilitating symptoms of narcolepsy. A 12% improvement in the ESS and 46% improvement in weekly cataplexy frequency are the thresholds indicating meaningful improvement over a 4-8 week period of treatment among a sample of mostly moderate to markedly ill patients with narcolepsy concurrently treated with stimulant therapy. Using these RD cut-offs, we showed a dose-response relationship with sodium oxybate demonstrating the validity of these thresholds. These RDs may be useful in describing patient-centred outcomes in future clinical trials or may be useful criteria to consider for clinical management.
We found only one recent study reporting outcome measurement properties for response to narcolepsy treatment (van der Heide et al., 2015) . Similar to the present ª 2017 European Sleep Research Society study, response was classified using Much Improved or Very Much Improved ratings on the CGI-c, and reported the ESS as an outcome. In contrast, their sample included patients with and without cataplexy, and the context was a trial evaluating modafinil, used to improve wakefulness, in which patients were allowed to continue sodium oxybate if already taking it. They compared outcomes for responders and nonresponders, based on the CGI-c, but their primary focus was on performance measures of sustained attention and wakefulness. Thus, RD thresholds were not reported. The authors confirmed the test-retest reliability of the ESS in patients with narcolepsy as well as its sensitivity to detect change, and showed an effect size of 1.2 between responders and nonresponders over an 8-week trial. A corresponding effect size using our data was 0.52 between responders and nonresponders (data not shown). This substantial difference illustrates the need to consider sample and agent characteristics when evaluating treatment response. We agree with van der Heide and colleagues who noted that treatment response might be best assessed by using complementary measures of different aspects of narcolepsy burden (van der Heide et al., 2015) . In our study, a reduction in cataplexy of at least 46% was a more sensitive measure for identifying response, and failure to show a 12% decrease or greater in sleepiness was slightly better at identifying non-response (Table 2 , sensitivity and specificity). Using both outcomes provides a more complete assessment of patient functioning. This study's strengths include a large sample, an anchorbased, statistical approach to identifying RD thresholds, and evaluation of two PROs. However, the findings would have been stronger if there had been an additional anchor representing the patient's perspective, such as a patient global rating of change. Unfortunately, a patient global rating of change was not captured in the two studies from which these data came. Similarly, multiple sleep latency tests would have been helpful for validating the RD thresholds but were also not collected. Another limitation was that our CGI-c anchor was dichotomized for the ROC analysis, leading to some loss of information. We did, however, present the moderate Spearman correlations using the continuous CGI-c measure to support its use as the anchor. Use of a dichotomized outcome is a criticism of responder analysis in general (Snapinn and Jiang, 2007) ; however, we felt the development of the RD thresholds using statistical methods would be useful for future therapeutic trials as well as a simple standard applicable to individuals for clinical management of patients. Finally, it should be noted that the CGI-c is a 'global' assessment that may have been informed by change in any symptom or side-effect and, was not specific to excessive daytime sleepiness and/or cataplexy frequency. Thus, these findings are most generalizable to a similar population of patients with narcolepsy considering treatment using similar agent properties, dose and duration.
In conclusion, we established two thresholds that can be applied to categorize individuals as having meaningful improvement within a 4-8 week trial of sodium oxybate. To our knowledge, we are the first to present RDs for the treatment of narcolepsy. While both RD thresholds were comparable for predicting response to treatment, excessive daytime sleepiness and cataplexy frequency are both important aspects of disease burden that should be considered in assessing patient response.
